生物
内质网
线粒体
脂肪性肝炎
脂肪变性
生物化学
细胞生物学
脂肪肝
病理
内分泌学
医学
疾病
作者
Qiyi Zhao,Jiayu Liu,Hong Deng,Ruiying Ma,Jian‐You Liao,Huixin Liang,Jingxiong Hu,Jiaqian Li,Zhiyong Guo,Junchao Cai,Xiaoding Xu,Zhiliang Gao,Shicheng Su
出处
期刊:Cell
[Elsevier]
日期:2020-09-14
卷期号:183 (1): 76-93.e22
被引量:294
标识
DOI:10.1016/j.cell.2020.08.009
摘要
Mitochondria, which play central roles in immunometabolic diseases, have their own genome. However, the functions of mitochondria-located noncoding RNAs are largely unknown due to the absence of a specific delivery system. By circular RNA (circRNA) expression profile analysis of liver fibroblasts from patients with nonalcoholic steatohepatitis (NASH), we observe that mitochondrial circRNAs account for a considerable fraction of downregulated circRNAs in NASH fibroblasts. By constructing mitochondria-targeting nanoparticles, we observe that Steatohepatitis-associated circRNA ATP5B Regulator (SCAR), which is located in mitochondria, inhibits mitochondrial ROS (mROS) output and fibroblast activation. circRNA SCAR, mediated by PGC-1α, binds to ATP5B and shuts down mPTP by blocking CypD-mPTP interaction. Lipid overload inhibits PGC-1α by endoplasmic reticulum (ER) stress-induced CHOP. In vivo, targeting circRNA SCAR alleviates high fat diet-induced cirrhosis and insulin resistance. Clinically, circRNA SCAR is associated with steatosis-to-NASH progression. Collectively, we identify a mitochondrial circRNA that drives metaflammation and serves as a therapeutic target for NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI